Navigation Links
Drug a New Treatment Option for Diabetic Eye Disease
Date:4/28/2010

Lucentis is first new therapy against diabetic macular edema in a quarter-century, experts say

WEDNESDAY, April 28 (HealthDay News) -- A new drug may be the first new treatment in 25 years for a common diabetes-linked eye condition called diabetic macular edema (DME), researchers report.

Lucentis (ranibizumab) was originally developed to treat age-related macular degeneration. But researchers say it can also improve vision in people with DME, a common form of diabetic retinopathy.

The study of 691 patients with DME found that 50 percent of those who received Lucentis eye injections, plus laser treatment if necessary, had substantial improvement in vision one year after treatment, compared with 28 percent of patients who received laser treatment alone. Results were similar after two years.

For 25 years, laser treatment has been the standard of care for DME, the main cause of vision loss in people with diabetes.

The study, published online in the journal Ophthalmology, was conducted by the Diabetic Retinopathy Clinical Research (DRCR) Network.

According to the U.S. National Eye Institute, DME occurs when fluid leaks into the center of the macula, the portion of the eye dedicated to sharp, straight-ahead vision. The condition is common in people with diabetic retinopathy, which affects up to 45 percent of people with diabetes.

The results of the new study "appear to be applicable to most people who have DME in the center of the macula with some vision loss, whether the person has type 1 or type 2 diabetes, is old or young, or is a woman or a man," Dr. Neil M. Bressler, chair of the DRCR Network and chief of the retina division, Wilmer Eye Institute, at Johns Hopkins University School of Medicine, said in a news release.

This is a "seminal" study," added Dr. George A. Williams, a board member of the American Academy of Ophthalmology and chair of the ophthalmology department at Oakland University William Beaumont School of Medicine.

"First and most importantly, it provides patients an improved therapy for diabetic macular edema. Second, the DRCR Network study is the first multi-center, randomized clinical trial to show how ranibizumab and the laser work together to improve treatment," Williams said.

The American Academy of Ophthalmology will review the study findings and make recommendations on whether Lucentis plus laser treatment should be the preferred treatment for a large number of patients with DME.

More information

The American Diabetes Association has more about diabetes-related eye complications.



-- Robert Preidt



SOURCE: American Academy of Ophthalmology, news release, April 27, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. CBDM.T, The Market and Business Intelligence Company Reviews The Dry Eye Disease Treatment Market
2. Study examines global availability of treatment involving transplantation of blood stem cells
3. Study finds that drugs used for treatment of influenza in pregnancy appear to be safe
4. Comparative-effectiveness study confirms new treatment for diabetic macular edema
5. Allergy Treatment from Absolute Health Provides Allergy Elimination as Opposed to Allergy Prevention
6. CureTogether Announces Online Autism Treatment Study
7. Nonmedical treatment may rapidly relieve severe IBS symptoms
8. New Varicose Vein Treatment Center Opens in Prescott, Arizona
9. Non-medical treatment may rapidly relieve severe IBS symptoms
10. Immune cells predict success of head and neck cancer treatment, U-M study finds
11. New report confirms fears of people living with HIV: Treatment rationing escalating
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and Nutrition ... the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market ... can be easily incorporated into liquid products, while reducing costs to end users. , ...
(Date:10/13/2017)... N.J. (PRWEB) , ... October 13, 2017 , ... The ... Holly Day Market. Featuring a collection of specialty vendors and unique items from across ... personalized and quality-focused health and wellness services offered by the VNA. The boutique ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... , Oct. 12, 2017 AVACEN Medical , ... company with their  2017 New Product Innovation Award for ... extensive primary and secondary medical device market research by Frost ... its first-to-market OTC, drug-free pain relief product, the AVACEN 100, ... to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)...  True Health, a leader in integrated diagnostics ... National Breast Cancer Awareness month to educate doctors ... Research recently published in ... than 10 million American women are at significant ... BRCA2 and have not had testing. These mutations can ...
(Date:10/5/2017)... 2017  In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...
Breaking Medicine Technology: